Cardiff Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cardiff Oncology, Inc. (CRDF) on April 9, 2026, covering events reported as of April 6, 2026. The filing primarily addresses significant changes to the Company's executive leadership team.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive appointments and associated compensation arrangements.
Material Changes
The Company announced the appointment of three new executive officers:
- Mani Mohindru, Ph.D. appointed President and Chief Executive Officer (effective April 9, 2026), transitioning from Interim CEO.
- Compensation: $655,000 base salary, $100,000 bonus, and 55% annual discretionary bonus.
- Equity: Granted 200,000 incentive stock options (exercise price $1.56) and 600,000 incentive stock options (exercise price $1.62) with four-year vesting schedules.
- Josh Muntner appointed Chief Financial Officer (effective April 6, 2026).
- Compensation: $475,000 base salary and 40% annual discretionary bonus.
- Equity: Granted 486,650 non-qualified stock options (exercise price $1.58) as an inducement grant, vesting over four years.
- Ajay Aggarwal, MD, MBA appointed Chief Operating Officer (effective April 27, 2026).
- Compensation: $490,000 base salary and 40% annual discretionary bonus.
- Equity: Expected to be granted 400,000 stock options.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of risks and contingencies. It strictly reports the personnel changes and confirms no undisclosed arrangements or family relationships exist between the new officers and current directors.
Key Facts for Investor Verification
- Verify the exact vesting schedules and performance conditions for the stock options granted to the new CEO, CFO, and COO.
- Confirm the total dilution impact of the 1,686,650 options granted to the new executive team.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for these leadership changes.
- Check subsequent filings for the formal adoption of the COO's stock option grant, which is currently listed as "expected."